GET DAILY SIGNALSWhy Is Pacific Biosciences of California (PACB) Stock Up +16.33% Today?
Key Takeaways
- PACB shares surged 16.33% to about $2.85, extending a powerful multi-week rally driven by a wave of artificial-intelligence and genomics partnerships.
- The primary catalyst is sustained momentum from strategic collaborations — including a multi-year deal with Verily Health and an AI drug-discovery pact with TychoBio — that position PacBio's HiFi long-read sequencing at the center of biomedical AI.
- Secondary drivers include a five-year, up to $27.1 million U.S. Department of Veterans Affairs contract announced via genomics provider Sampled, and a Stephens analyst price-target raise to $2.50 from $1.50.
- The stock has been highly volatile and has roughly doubled over the past month, with heavy call-option buying and possible short covering amplifying the move.
- Traders are watching the company's third-quarter earnings report, scheduled for November 4, 2026, as the next major catalyst.
- For deeper data on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- To discover AI-driven trading strategies tuned to current market conditions, visit Trending AI Robots.
Opening Summary
Pacific Biosciences of California, Inc. (PACB), commonly known as PacBio, is a Menlo Park, California-based developer of high-accuracy long-read DNA and RNA sequencing systems, including its Revio and Vega platforms and HiFi sequencing technology. In today's session, the stock climbed 16.33%, recently trading around $2.85 versus a prior close of $2.45, confirming a sharp upward move. Markets attributed the advance to continued enthusiasm around PacBio's growing roster of artificial-intelligence and genomics collaborations, which investors see as expanding the company's addressable market well beyond traditional research instruments.
AI and Genomics Partnership Momentum
The strongest driver behind the rally is a string of recent strategic announcements that have repositioned PACB as a key enabler of AI-powered biology. In mid-October, the company unveiled a multi-year collaboration with Verily Health to integrate PacBio HiFi sequencing into Verily's governed data and AI platform, linking long-read genomic data with multimodal health records and AI-ready research workflows. That followed an October pact with TychoBio, under which PacBio will generate full-length RNA data from more than 10,000 samples to train AI models for rare-disease RNA therapeutics.
These deals build on earlier announcements, including the EpiSign METRIC 5-base launch that enables DNA methylation analysis across more than 300 episignature disorders, and Basecamp Research's selection of HiFi sequencing for its Trillion Gene Atlas. Collectively, the agreements reinforce a narrative that PacBio's long-read data is becoming a foundational input for AI drug discovery — a theme that has driven sustained buying interest across the genomics sector.
Government Contract and Analyst Support
Additional catalysts added fuel to the move. Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support the Million Veteran Program using PacBio Revio systems, underscoring recurring demand from large-scale population-sequencing initiatives. On the analyst front, Stephens raised its price target on PACB to $2.50 from $1.50 while maintaining an Overweight rating, signaling increased conviction in the company's clinical and consumables trajectory even as broader sentiment on the stock remains mixed.
Short Squeeze and Technical Breakout
The magnitude of the move also reflects technical and positioning dynamics. PacBio is a heavily shorted, high-beta small-cap that has recorded numerous single-day moves exceeding 5% over the past year. Unusually heavy call-option buying — at times several hundred percent above average — along with a sharp climb through the 50-day and 200-day moving averages, has created conditions ripe for short covering and momentum chasing. As the stock broke above prior resistance levels and set fresh multi-month highs, forced buying from short sellers likely amplified the upside.
Market Context and Trading Activity
Trading volume has been elevated relative to the norm. The prior session saw roughly 18.7 million shares change hands, well above the stock's typical daily average of around 8 to 11 million shares, indicating strong conviction rather than a low-liquidity drift. The advance has outpaced the broader market, with PACB posting gains of more than 20% over the past week and roughly 40% over the past month, even as concerns about rising Treasury yields have pressured some growth and healthcare names. The move appears idiosyncratic — tied to company-specific catalysts — rather than a broad sector rotation.
What Comes Next for PACB
Attention now turns to PacBio's third-quarter 2026 earnings report, scheduled for November 4, 2026, with management also set to appear at upcoming investor conferences including the UBS Global Healthcare event. Investors will scrutinize consumables pull-through, Revio and Vega placements, and progress on the SPRQ-Nx chemistry transition, against a backdrop of lowered full-year revenue guidance and a cash-flow breakeven target pushed to 2028. While the AI-partnership narrative has driven momentum, risks remain: the company is unprofitable, faces funding headwinds in research markets, and carries a beta above 2.0, making it vulnerable to sharp reversals if sentiment cools or the earnings report disappoints.
Trending AI Robots
Tickeron's Trending AI Robots page highlights the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots spanning thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. Only the bots demonstrating the most robust recent performance are curated into the Trending AI Robots section, giving traders a focused view of which automated strategies are adapting best to today's markets. Explore the section to see which AI strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PACB sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PACB as a result. In 73 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The 10-day moving average for PACB crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +16.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 222 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 116 of 138 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for PACB moved out of overbought territory on October 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 28 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-26.485) is slightly lower than the industry average of (3.837). P/E Ratio (-6.738) is within average values for comparable stocks, (2.078). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of sequencing system products to help scientists to resolve genetically complex problems
Industry MedicalNursingServices
Advertisement